BeyondSpring Inc. (BYSI)
BYSINASDAQ-CMBiotechnology: Pharmaceutical Preparations
$0.5797
-0.0373 (-6.05%) today
Closed, Nov 10, 4:00 PM ET
- Market cap
- $23.84m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.4215 to $2.44
- Average volume
- 312.2k
- Previous close
- $0.6170
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$1.79m | -$2.60m | -$2.23m | -$1.73m |
| Net income | -$1.54m | -$2.14m | -$2.16m | -$849.0k |
News
7 latest- BeyondSpring Gets FDA Fast Track For Plinabulin In Lung Cancer RTTNews · Sep 29, 2026
- BeyondSpring Cash Jumps in Fiscal Q2The Motley Fool · Aug 13, 2025
- BeyondSpring Inc. Reports Promising Results of Plinabulin Combination Therapy in Patients Refractory to Immune Checkpoint InhibitorsQuiver Quantitative · Jul 7, 2025
- BeyondSpring Inc. Reports Promising Interim Phase 2 Data for Plinabulin in Metastatic NSCLC Showing 6.8 Months Median PFS and 78% Overall Survival RateQuiver Quantitative · Jun 3, 2025
- BeyondSpring Inc. Reports Positive Early Results for Plinabulin in Metastatic Cancer and Updates on SEED Therapeutics' ProgressQuiver Quantitative · May 12, 2025
- BeyondSpring Inc. Full Year Loss Declines RTTNews · Mar 27, 2025
- BeyondSpring Inc. Announces $35.4 Million Sale of Series A-1 Preferred Shares in SEED TherapeuticsQuiver Quantitative · Jan 28, 2025
The company
BeyondSpring (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies for cancers with high unmet needs. Its lead asset, Plinabulin, has been studied in over 700 cancer patients and is in late-stage development across multiple cancer indications, with results published in The Lancet Respiratory Medicine. Plinabulin's novel mechanism as a GEF-H1 agonist with dendritic cell maturation benefit supports both anticancer activity and immune modulation, offering a unique approach to re-sensitizing tumors resistant to checkpoint inhibitors. In addition, it has the potential to synergize with chemotherapy, antibody-drug conjugates (ADCs), radiation, and checkpoint inhibitors.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- beyondspringpharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.